Application of G-CSF in high-leukocyte acute myeloid leukemia is a poor prognostic factor

References

• Bendall LJ, Bradstock KF. G-CSF: from granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev. 2014;25:355–367.
   PubMed Web of Science ®Google Scholar
• Law KB, Chang KM, Hamzah NA, et al. Fludarabine, high dose cytarabine and granulocyte colony-stimulating factor (FLAG) as consolidation chemotherapy in older patients with acute myeloid leukemia: a retrospective cohort study. Indian J Hematol Blood Transfus. 2017;33:483–491.
   PubMed Web of Science ®Google Scholar
• Saini L, Brandwein J, Turner R, et al. The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease. Eur J Haematol. 2016;97:471–478.
   PubMed Web of Science ®Google Scholar
• Liongue C, Wright C, Russell AP, et al. Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. Int J Biochem Cell Biol. 2009;41:2372–2375.
   PubMed Web of Science ®Google Scholar
• Curtis DJ, Metcalf D, Alexander B, et al. Leukemic cells from murine myeloid leukemia display an intrinsic ability for autonomous proliferation. Exp Hematol. 2000;28:36–45.
   PubMed Web of Science ®Google Scholar
• Zhang ZN, editor. Blood disease diagnosis and efficacy standard. 3rd ed. Beijing: Science Press; 2007, p. 131–134.
   Google Scholar
• Teuffel O, Leibundgut K, Lehrnbecher T, et al. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol. 2013;161:192–203.
   PubMed Web of Science ®Google Scholar
• Valcarcel D, Montesinos P, Sanchez-Ortega I, et al. A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. Cancer. 2012;118:410–417.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Lensing S, Zhou Y, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer. 2004;101:1677–1684.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199–3212.
   PubMed Web of Science ®Google Scholar
• Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727–731.
   PubMed Web of Science ®Google Scholar
• Beksac M, Ali R, Ozcelik T, et al. Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial. Leuk Res. 2011;35:340–345.
   PubMed Web of Science ®Google Scholar
• Nomdedeu M, Lara-Castillo MC, Etxabe A, et al. Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. Cancer Cell Int. 2015;15:122.
   PubMed Web of Science ®Google Scholar
• Martinez-Cuadron D, Boluda B, Martinez P, et al. A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. Ann Hematol. 2018;97(5).
   Web of Science ®Google Scholar
• Uy GL, Rettig MP, Stone RM, et al. A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. Blood Cancer J. 2017;7:e542.
   PubMed Web of Science ®Google Scholar
• Liu XM, Chen YZ, et al. The potential prognostic influence of granulocyte-colony stimulating factor in acute leukemia. Chin J Intern Med. 2005;44(7):518–521.
   PubMedGoogle Scholar
• Wheatley K, Goldstone AH, Littlewood T, et al. Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol. 2009;146:54–63.
   PubMed Web of Science ®Google Scholar
• Sperr WR, Herndlhofer S, Gleixner K, et al. Intensive consolidation with G-CSF support: tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients >/=60 years. Am J Hematol. 2017;92:E567–E574.
   PubMed Web of Science ®Google Scholar
• Kang KW, Kim DS, Lee SR, et al. Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies. Leuk Res. 2017;57:1–8.
   PubMed Web of Science ®Google Scholar
• Minakata D, Fujiwara SI, Ikeda T, et al. Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia. Int J Hematol. 2017;106:411–417.
   PubMed Web of Science ®Google Scholar
• Osuorji I, Goldman L. G-CSF-associated bone marrow necrosis in AML after induction chemotherapy. Case Rep Hematol. 2012;2012:314278.
   PubMedGoogle Scholar
• Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol. 2003;72:82–93.
   PubMed Web of Science ®Google Scholar
• Kutlay S, Beksac M, Dalva K, et al. The detection of flow cytometric G-CSF receptor expression and it's effect on therapy in acute myeloid leukemia. Leuk Lymphoma. 2003;44:791–795.
   PubMed Web of Science ®Google Scholar
• Ehlers S, Herbst C, Zimmermann M, et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol. 2010;28:2591–2597.
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen YY, Chen YZ. Expression of G-CSFRIV isoform in adult acute myeloid leukemia and its clinical significance. J Exp Hematol. 2014;22(4):899–902.
   Google Scholar